Incyte crosses $1B in quarterly revenue for the 1st time, even as Jakafi faces off against GSK rival fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.
Westlake Village-based Arcutis Biotherapeutics announced that its main treatment option, Zoryve, received approval from the U.S. Drug and Food Administration for treating a skin condition called seborrheic dermatitis, the company announced on Dec. 15 It is the second FDA approval received by Arcutis’ Zoryve, being approved to be used in individuals nine years of age